Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Stock analysts at HC Wainwright issued their Q4 2024 EPS estimates for Perspective Therapeutics in a note issued to investors on Thursday, March 13th. HC Wainwright analyst R. Burns forecasts that the company will earn ($0.24) per share for the quarter. HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Perspective Therapeutics' Q1 2025 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.33) EPS and FY2025 earnings at ($1.19) EPS.
Several other research analysts also recently weighed in on the stock. Royal Bank of Canada reiterated an "outperform" rating and issued a $16.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. Oppenheimer decreased their price target on shares of Perspective Therapeutics from $22.00 to $16.00 and set an "outperform" rating on the stock in a research report on Friday, November 22nd. Lifesci Capital upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Thursday, March 6th. Wedbush restated an "outperform" rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research report on Monday. Finally, Bank of America downgraded shares of Perspective Therapeutics from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $24.00 to $5.00 in a research report on Monday, November 25th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $14.56.
Check Out Our Latest Analysis on CATX
Perspective Therapeutics Trading Down 5.8 %
CATX stock traded down $0.15 on Friday, hitting $2.45. The company had a trading volume of 783,966 shares, compared to its average volume of 984,482. Perspective Therapeutics has a 12-month low of $2.32 and a 12-month high of $19.05. The stock's 50-day simple moving average is $3.12 and its 200 day simple moving average is $7.11.
Institutional Investors Weigh In On Perspective Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CATX. Charles Schwab Investment Management Inc. raised its holdings in shares of Perspective Therapeutics by 221.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company's stock valued at $5,788,000 after purchasing an additional 298,778 shares in the last quarter. State Street Corp raised its holdings in shares of Perspective Therapeutics by 119.6% in the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company's stock valued at $29,240,000 after purchasing an additional 1,192,812 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Perspective Therapeutics by 8.0% in the 3rd quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company's stock valued at $64,014,000 after purchasing an additional 355,685 shares in the last quarter. FMR LLC raised its holdings in shares of Perspective Therapeutics by 3,994.9% in the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company's stock valued at $73,489,000 after purchasing an additional 5,370,392 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in shares of Perspective Therapeutics by 1,302.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company's stock valued at $635,000 after purchasing an additional 44,174 shares in the last quarter. Institutional investors own 54.66% of the company's stock.
About Perspective Therapeutics
(
Get Free Report)
Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
See Also
Before you consider Perspective Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Perspective Therapeutics wasn't on the list.
While Perspective Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
